Baricitinib for arthritis from CPPD crystals
Treatments studied
Part of Bones, joints & muscles clinical trials.
This study tests if baricitinib, an anti-inflammatory pill, can help people with arthritis caused by CPPD crystals (also called pseudogout). It is for people aged 55 and older who have swelling in their hands/wrists or large joints.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older.
- You have a diagnosis of CPPD disease (pseudogout).
- You have active arthritis or tendon swelling in your hands/wrists, or repeated attacks in large joints.
- You are willing and able to have a small tissue sample (biopsy) taken from your knee or wrist.
- Women must be past menopause (no period for 12 months). Men must use effective birth control or have a partner past menopause.
- You do not have recent serious infections, blood clots, cancer, or other conditions that make baricitinib unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if tocilizumab can help people with chronic pain from CPPD crystal arthritis (also called pseudogout). It is for people whose pain has not responded to usual treatments like colchicine, NSAIDs, or steroids.
This study looks at calcium pyrophosphate deposition (CPPD) disease, which causes joint inflammation. It aims to understand the disease better by studying people with either an acute first episode or ongoing chronic CPPD arthritis.
This study looks at people with certain types of crystal deposits in joints (like gout, CPPD, or hydroxyapatite crystal disease). It uses scans such as ultrasound and a special CT-type scan called DECT to confirm and better understand what’s causing your symptoms.
This trial tests if colchicine can reduce pain and swelling in people with CPPD (calcium pyrophosphate deposition disease), a type of arthritis. If you have had a swollen, red, or warm joint in the last 3 months and your pain is moderate or higher, this study may offer a possible treatment.
This trial tests if adding baricitinib (a pill that calms inflammation) to standard steroids works better than steroids alone for people with polymyalgia rheumatica. It aims to improve symptoms and reduce steroid side effects.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
Hear when a new Calcium Pyrophosphate Deposition Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.